Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies

Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies

The efficacy of mesenchymal stem cell infusion is currently tested in numerous clinical trials. However, therapy-induced thrombotic consequences have been reported in several patients. The aim of this study was to optimize protocols for heterologous human adult liver-derived progenitor cell (HHALPC)...

Full description

Bibliographic Details
Main Authors: Louise Coppin, Mustapha Najimi, Julie Bodart, Marie-Sophie Rouchon, Patrick van der Smissen, Stéphane Eeckhoudt, Géraldine Dahlqvist, Diego Castanares-Zapatero, Mina Komuta, Sanne L. Brouns, Constance C. Baaten, Johan W. M. Heemskerk, Sandrine Horman, Nathalie Belmonte, Etienne Sokal, Xavier Stéphenne
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cells
Subjects:
cell- and tissue-based therapy
liver transplantation
mesenchymal stem cells
thrombosis
anticoagulants
Online Access:https://www.mdpi.com/2073-4409/8/8/846

Internet

https://www.mdpi.com/2073-4409/8/8/846

Similar Items